<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Clinical Trials - Brain and Spine</title>
    <link rel="stylesheet" href="styles.css">
    <link rel="icon" href="favicon.ico">
    <link href="https://fonts.googleapis.com/css2?family=Roboto:wght@400;700&display=swap" rel="stylesheet">
    <style>
        body {
            font-family: 'Roboto', sans-serif;
            margin: 0;
            padding: 0;
            color: #333;
        }
        header {
            background-color: #004E25;
            color: #fff;
            padding: 1rem 0;
            text-align: center;
        }
        nav {
            background-color: #003B1A;
            padding: 0.5rem 0;
        }
        nav ul {
            list-style: none;
            margin: 0;
            padding: 0;
            display: flex;
            justify-content: center;
        }
        nav ul li {
            margin: 0 1rem;
        }
        nav ul li a {
            color: #fff;
            text-decoration: none;
            font-weight: bold;
        }
        nav ul li a:hover {
            text-decoration: underline;
        }
        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 1rem;
        }
        section {
            padding: 2rem;
            margin: 2rem 0;
            border-radius: 8px;
            box-shadow: 5px 10px 15px rgba(0, 0, 0, 0.3);
        }
        section:nth-of-type(odd) {
            background-color: #f4f4f4;
        }
        section:nth-of-type(even) {
            background-color: #e0e0e0;
        }
        h2 {
            text-align: center;
            color: #004E25;
        }
        ul {
            list-style: none;
            padding: 0;
        }
        ul li {
            margin: 0.5rem 0;
        }
        ul li a {
            color: #004E25;
            text-decoration: none;
        }
        ul li a:hover {
            text-decoration: underline;
        }
		footer {
            background-color: #003B1A;
            color: #fff;
            text-align: center;
            padding: 1rem 0;
            margin-top: 2rem;
            width: 100%;
        }
    </style>
</head>
<body>
    <header>
        <h1>Clinical Trials for CNS Tumors at Rush</h1>
    </header>
    
    <nav>
        <ul>
            <li><a href="../index.html">Home</a></li>
            <li><a href="#active">Active Trials</a></li>
            <li><a href="#soon">Set to Open</a></li>
            <li><a href="#closed">Recently Closed</a></li>
			<li><a href="#abbrv">Abbreviation Glossary</a></li>
        </ul>
    </nav>

    <div class="container">
        <section id="info">
		<h2>General Information</h2>
            		Most trials open at Rush University Medical Center for CNS tumors are for patients 18 years of age and older, though there may be exceptions. Trials will also generally require patients to be healthy enough to undergo the proposed treatment being examined in the trial. Details about trial eligibility can be discussed with your <a href="https://www.rush.edu/services/brain-tumor-care">Rush provider</a>, though some information is also linked to here. 
		<br>
		<center>Last Updated: 2024 December 13</center>
        </section>

        <section id="active">
            <a href="https://www.rush.edu/clinical-trials?area=481" style="text-decoration: none;"><h2>Currently Active Clinical Trials</h2></a><br>
            <ul>
                <li><b>Brain Metastases</b></li>
				<ul>
					<li><a href="https://www.rush.edu/clinical-trials/post-surgical-srt-versus-start-gamma-tile-treatment-newly-diagnosed-metastatic">ROADS</a>: GammaTile Brachytherapy vs Postoperative SRS for Resected Brain Metastases</li>
					
				</ul><br>
				
				<li><b>GBM</b></li>	
				<ul>
					<li><a href="#">GESTALT</a>: Feasibility Study of Resection and GammaTile Followed by Concomitant EBRT and TMZ and Adjuvant TMZ in Newly Diagnosed GBM</li>
				</ul><br>
				
				<li><b>Meningioma</b></li>
				<ul>
					<li><a href="https://www.rush.edu/clinical-trials/observation-or-radiation-therapy-treating-patients-newly-diagnosed-grade-ii">NRG-BN003</a>: Observation vs Radiation for Completely Resected Grade 2 Meningioma</li>
					<li><a href="https://www.rush.edu/clinical-trials/meningioma-drug-treatment-study">A071401</a>: Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations</li>
				</ul><br>

				<li><b>Other</b></li>
				<ul>
					<li>---</li>
				</ul><br>
				
				<li><b>Spine</b></li>
				<ul>
					<li><a href="https://www.rush.edu/clinical-trials/registry-management-and-outcome-metastatic-spine-tumors">MTRON</a>: Multicenter Prospective Registry for the Management and Outcome of Metastatic Spine Tumors</li>
				</ul>
            </ul>
        </section>

        <section id="soon">
            <h2>Clinical Trials Set to Open Soon</h2>
            <ul>
                <li><b>Brain Metastases</b></li>
				<ul>
					<li><a href="#">JLF-200</a>: Neoantigen Therapeutic Cancer Vaccine Study</li>
					<li><a href="#">NRG-BN013</a>: Phase III Trial of Single Fraction SRS vs Fractionated SRS for Intact Brain Metastases</li>
				</ul><br>
				
				
				<li><b>GBM</b></li>	
				<ul>
					<li><a href="#">A072201</a>: Radnomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs SOC in Recurrent GBM</li>
				<ul>
				</ul><br>
				
				<li><b>Meningioma</b></li>
				<ul>
					<li>---</li>
				</ul><br>

				<li><b>Other</b></li>
				<ul>
					<li>---</li>
				</ul><br>
				
				<li><b>Spine</b></li>
				<ul>
					<li>---</li>
				</ul>
            </ul>
        </section>

        <section id="closed">
            <h2>Clinical Trials Closed at RUMC</h2>
                        <ul>
                <li><b>Brain Metastases</b></li>
				<ul>
					<li><a href="#">A071701</a>: Genomically-Guided Treatment Trial in Brain Metastases</li>
					<li><a href="#">NRG-BN009</a>: Phase III Trial of Salvage SRS vs SRS with HA-WBRT for Brain Metastasis Relapse (>/= 4 brain metastases/year)</li>
					<li><a href="#">NRG-CC003</a>: Randomized Phase II/III Trial of PCI with or without HA-WBRT for SCLC</li>
					<li><a href="#">NRG-CC009</a>: Phase III Trial of SRS vs HA-WBRT for 10 or Fewer Brain Metastases in SCLC</li>
				</ul><br>
				
				<li><b>GBM</b></li>	
				<ul>
					<li><a href="#">NRG-BN010</a>: Phase II Study of Combination Tocilizumab, Atezolizumab, and fSRS in Recurrent GBM</li>
					<li><a href="#">A071102</a>: A Phase II/III Randomized trial of Veliparib or Placebo with Adjuvant TMZ in Newly Diagnosed GBM with MGMT Methylation</li>
					<li><a href="#">A071101</a>: Phase II Randomized Trail Comparing HSPPC-96 Vaccine Given with Bevacizumab vs Bevacizumab Alone for Resectable Recurrent GBM</li>
					<li><a href="#">CNS-201</a>: Open-Label Study of IV Berubicin in Recurrent GBM After Failure of Standard FLT</li>
					<li><a href="#">Enzasturin</a>: Trial for Newly Diagnosed GBM Patients with Biomarker DGM1</li>
					<li><a href="#">TRIDENT / EF-32</a>: A Phase III Randomized, open-label study of Optune (TTFields) concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma</li>
				<ul>
				</ul><br>
				
				<li><b>Meningioma</b></li>
				<ul>
					<li>---</li>
				</ul><br>

				<li><b>Other</b></li>
				<ul>
					<li><a href="#">A071601</a>: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas</li>
				</ul><br>
				
				<li><b>Spine</b></li>
				<ul>
					<li>---</li>
				</ul>
            </ul>
        </section>
		
		<section id="abbrv">
			<h2>Abbreviations</h2>
            <ul class="glossary-list">
                <li>GBM: Glioblastoma</li>
                <li>SRS: Stereotactic Radiosurgery</li>
				<li>fSRS: Fractionated Stereotactic Radiosurgery</li>
                <li>TMZ: Temozolomide</li>
                <li>TTD: Tumor Treating Fields</li>
				<li>MRI: Magnetic Resonance Imaging</li>
				<li>FLT: First Line Therapy</li>
				<li>HA-WBRT: Hippocampal Avoidant Whole Brain Radiotherapy</li>
				<li>SCLC: Small Cell Lung Cancer</li>
				<li>PCI: Prophylactic Cranial Irradiation</li>
				<li>CNS: Central Nervous System (Brain and Spine)</li>
				<li>SOC: Standard of Care</li>
				<li>RUMC: Rush University Medical Center</li>
			</ul>
		</section>
    </div>

<script>
	/* Keep glossary in alphabetical order */
    document.addEventListener("DOMContentLoaded", function() {
        const glossaryList = document.querySelector('.glossary-list');
        const items = Array.from(glossaryList.querySelectorAll('li'));

        items.sort((a, b) => {
            const textA = a.textContent.trim().toUpperCase();
            const textB = b.textContent.trim().toUpperCase();
            return textA.localeCompare(textB);
        });

        // Clear the existing list
        glossaryList.innerHTML = '';

        // Append the sorted items
        items.forEach(item => glossaryList.appendChild(item));
    });
</script>


    <footer>
        <p>Â© Tatebe Lab - Radiation Oncology, Physics, Imaging, and Data Science</p>
    </footer>
</body>
</html>
